The term “microbiome” refers to all of the microorganisms (including bacteria, fungi, and other living things) that live inside and on the surface of the human body. There is growing evidence that the microbiome plays a large role in our overall health and wellbeing.
EDP1503 is a genetically engineered bacterium that can be taken orally and incorporated into the healthy gut microbiome. Once there, EDP1503 enhances the body’s immune response against cancerous cells by increasing the number of tumour-fighting white blood cells.
Meanwhile, Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targeting a molecule called PD-1 to activate the body’s immune defences n order to target and destroy cancer cells.
This study will investigate the safety and effectiveness of EDP1503 when taken in combination with Pembrolizumab.
In order to maximize effectiveness and minimize side effects, difference doses of each drug will be used to determine the optimal dosage of these medications.
- All subtypes eligible
- Advanced kidney cancer that cannot be removed by surgery
- Must have received, and subsequently stopped responding to, an immunotherapy treatment
Additional eligibility criteria will apply. Please speak to your doctor.Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreCentre de Recherche du CHUM||Principal InvestigatorDr. Johanna Bendell||LocationMontreal, QC||Trial StatusRecruiting|
|Hospital / Cancer CentreCHU de Québec - Université Laval||Principal InvestigatorDr. Johanna Bendell||LocationQuebec City, QC||Trial StatusRecruiting|
|Hospital / Cancer CentreJewish General Hospital||Principal InvestigatorDr. Johanna Bendell||LocationMontreal, QC||Trial StatusRecruiting|